New blood test may predict cancer relapse after transplant

NCT ID NCT07607327

Not yet recruiting Knowledge-focused Sponsor: CareDx Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have a stem cell transplant for AML, MDS, or CMML will take part. The study does not provide treatment, but aims to improve how doctors monitor for relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia chronic myelomonocytic leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA) CMML MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CareDx, Inc.

Brisbane, California, 94080, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••